Day Return On Equity from 2010 to 2024

DAWN Stock  USD 13.34  0.28  2.06%   
Day One Return On Equity yearly trend continues to be very stable with very little volatility. Return On Equity is likely to grow to -0.52 this year. Return On Equity is a measure of the profitability of Day One Biopharmaceuticals in relation to the equity, calculated by dividing net income by shareholder's equity. View All Fundamentals
 
Return On Equity  
First Reported
2010-12-31
Previous Quarter
(0.55)
Current Value
(0.52)
Quarterly Volatility
0.68853919
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Day One financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Day One's main balance sheet or income statement drivers, such as Net Interest Income of 5.7 M, Depreciation And Amortization of 34.2 K or Interest Expense of 5.7 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 3.53. Day financial statements analysis is a perfect complement when working with Day One Valuation or Volatility modules.
  
Check out the analysis of Day One Correlation against competitors.

Latest Day One's Return On Equity Growth Pattern

Below is the plot of the Return On Equity of Day One Biopharmaceuticals over the last few years. Return on Equity is the amount of Day One Biopharmaceu net income returned as a percentage of Day One equity. Return on equity measures Day One profitability by revealing how much profit Day One Biopharmaceuticals generates with the money shareholders have invested. It is a measure of the profitability of a business in relation to the equity, calculated by dividing net income by shareholder's equity. Day One's Return On Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Day One's overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported -0.1810 Years Trend
Slightly volatile
   Return On Equity   
       Timeline  

Day Return On Equity Regression Statistics

Arithmetic Mean0.97
Geometric Mean1.02
Coefficient Of Variation71.19
Mean Deviation0.55
Median1.38
Standard Deviation0.69
Sample Variance0.47
Range1.9235
R-Value(0.80)
Mean Square Error0.18
R-Squared0.64
Significance0.0003
Slope(0.12)
Total Sum of Squares6.64

Day Return On Equity History

2024 -0.52
2023 -0.55
2022 0.49
2021 0.55
2020 0.75

About Day One Financial Statements

Day One investors utilize fundamental indicators, such as Return On Equity, to predict how Day Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Return On Equity(0.55)(0.52)

Pair Trading with Day One

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Day One position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Day One will appreciate offsetting losses from the drop in the long position's value.

Moving against Day Stock

  0.37KTTA Pasithea TherapeuticsPairCorr
  0.33MRK Merck Company Fiscal Year End 6th of February 2025 PairCorr
  0.32PALI Palisade BioPairCorr
The ability to find closely correlated positions to Day One could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Day One when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Day One - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Day One Biopharmaceuticals to buy it.
The correlation of Day One is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Day One moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Day One Biopharmaceu moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Day One can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Day One Biopharmaceu offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Day One's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Day One Biopharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Day One Biopharmaceuticals Stock:
Check out the analysis of Day One Correlation against competitors.
You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Day One. If investors know Day will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Day One listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.97)
Revenue Per Share
1.144
Return On Assets
(0.25)
Return On Equity
(0.18)
The market value of Day One Biopharmaceu is measured differently than its book value, which is the value of Day that is recorded on the company's balance sheet. Investors also form their own opinion of Day One's value that differs from its market value or its book value, called intrinsic value, which is Day One's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Day One's market value can be influenced by many factors that don't directly affect Day One's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Day One's value and its price as these two are different measures arrived at by different means. Investors typically determine if Day One is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Day One's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.